comprehensive -WSS

comprehensive

author：leisure time 2025-09-27 16:35:40 - browse：9918

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： UnitedHealth’s board chair also owns a personal investment firm

WSS

STAT Readout Newsletter: Today's biggest biotech updates

Diversity in medical illustrations gets boost from Chidiebere Ibe

As pharma fights Medicare drug negotiation, hospitals, docs silent

2023 STAT Wunderkinds: get to know the winners

CEOs share strategies for surviving biotech slump

FDA struggles to regulate food additives, sometimes for decades

entertainment

comprehensive

Wikipedia

At least 13 dead in Texas as scorching temps continue

How climate

The cancer drug shortage isn’t new — and neither are the solutions

Diversity in medical illustrations gets boost from Chidiebere Ibe

Walensky prepares to leave CDC — and Congress — behind

UnitedHealth’s board chair also owns a personal investment firm

Walensky prepares to leave CDC — and Congress — behind

The EU Joint Clinical Assessment needs to live up to its promise

BioMarin wins approval for gene therapy to treat hemophilia A

STAT Readout Newsletter: Today's biggest biotech updates

focus

Psilocybin's anti

STAT Summit: GSK CEO on pharma giant's new direction

Winners, losers from Medicare’s list of drugs subject to price talks

Beam Therapeutics to lay off 20% of its staff, re

Senate committee scrutinizes Medicare Advantage brokers

Medicare explains how it will choose drugs for negotiation

hotspot

Wikipedia

entertainment

focus